- Home
- QNRX vs AQMS Comparison
QNRX vs AQMS Comparison
Compare QNRX & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- AQMS
- Stock Information
- Founded
- QNRX 2018
- AQMS 2014
- Country
- QNRX United States
- AQMS United States
- Employees
- QNRX 3
- AQMS N/A
- Industry
- QNRX Medical/Dental Instruments
- AQMS Metal Fabrications
- Sector
- QNRX Health Care
- AQMS Industrials
- Exchange
- QNRX Nasdaq
- AQMS Nasdaq
- Market Cap
- QNRX 4.8M
- AQMS 5.1M
- IPO Year
- QNRX N/A
- AQMS 2015
- Fundamental
- Price
- QNRX $8.59
- AQMS $3.96
- Analyst Decision
- QNRX
- AQMS Buy
- Analyst Count
- QNRX 0
- AQMS 1
- Target Price
- QNRX N/A
- AQMS $30.00
- AVG Volume (30 Days)
- QNRX 107.3K
- AQMS 38.3K
- Earning Date
- QNRX 11-06-2025
- AQMS 11-13-2025
- Dividend Yield
- QNRX N/A
- AQMS N/A
- EPS Growth
- QNRX N/A
- AQMS N/A
- EPS
- QNRX N/A
- AQMS N/A
- Revenue
- QNRX N/A
- AQMS N/A
- Revenue This Year
- QNRX N/A
- AQMS N/A
- Revenue Next Year
- QNRX N/A
- AQMS $550.00
- P/E Ratio
- QNRX N/A
- AQMS N/A
- Revenue Growth
- QNRX N/A
- AQMS N/A
- 52 Week Low
- QNRX $5.01
- AQMS $3.37
- 52 Week High
- QNRX $54.95
- AQMS $46.00
- Technical
- Relative Strength Index (RSI)
- QNRX 70.88
- AQMS 49.77
- Support Level
- QNRX $7.35
- AQMS $3.56
- Resistance Level
- QNRX $7.79
- AQMS $4.30
- Average True Range (ATR)
- QNRX 0.38
- AQMS 0.31
- MACD
- QNRX 0.13
- AQMS 0.08
- Stochastic Oscillator
- QNRX 46.79
- AQMS 51.25
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.